CompletedNCT05839041
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
PHASE2 · 300 planned enrolment
- Countries listed
- 1
- Registry update
- September 16, 2026
immortal.lifePublic trial registrations naming Aviceda Therapeutics, Inc. as an industry lead sponsor.
This is an independent registry-name view, not a verified corporate profile, portfolio valuation, ownership map, endorsement, or investment recommendation.
This does not mean that no transaction exists. A record appears only after its disclosure source and the connection to this exact registry sponsor identity are separately verified.
PHASE2 · 300 planned enrolment